Pharmaceuticals

Atea Pharmaceuticals

Atea Pharmaceuticals released FY2026 Q1 earnings during market hours on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5737 (forecast USD -0.59)

Atea Pharmaceuticals to Release FY2026 Q1 Earnings on May 12 During-Market EST, Forecasted Revenue USD 0, EPS USD -0.59

Atea Pharmaceuticals released FY2025 Q4 earnings on March 5 After-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5742 (forecast USD -0.53)

Atea Pharmaceuticals released FY2025 Annual Earnings on March 5 After-Market (EST), Actual Revenue: USD 0 (Forecast: USD 0), Actual EPS: USD -1.943 (Forecast: USD -1.9)

Atea Pharmaceuticals to Release FY2025 Q4 Earnings on March 5 After-Market EST, Forecast EPS -0.53 USD

Atea Pharmaceuticals Inc. Outlines 2026 Strategic Priorities at JPM Healthcare Conference

Atea Pharmaceuticals released FY2025 9 Months Earnings on November 12 After-Market EST with actual revenue of USD 0 and EPS of USD -1.378

Atea Pharmaceuticals released FY2025 Q3 earnings on November 12 After-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5319 (forecast USD -0.44)

Atea Pharmaceuticals to Release FY2025 Q3 Earnings on November 12 After-Market EST, Forecast EPS USD -0.44

Atea Pharmaceuticals released FY2025 Semi-Annual Earnings on August 7 During-Market EST, Actual Revenue USD 0, Actual EPS USD -0.8458

Atea Pharmaceuticals released FY2025 Q2 earnings on August 7 During-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4437 (forecast USD -0.45)

Atea Pharmaceuticals to release FY2025 Q2 earnings on August 7, during market hours EST, with forecasted EPS of USD -0.45

Atea's Q2 Revenue Growth Misses Expectations, Stock Price Falls

Atea Pharmaceuticals Inc Doses First Patient Outside North America in C-FORWARD Study

Atea Pharmaceuticals released FY2025 Q1 earnings on May 12 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4024 (forecast USD -0.4107)

Atea Pharmaceuticals Reports Q1 Earnings and Advances HCV Treatment Study

Atea Pharmaceuticals reports a Q1 EPS loss of $0.4

Atea Pharmaceuticals Inc Expected to Report Q1 EPS Loss of 41 Cents

Atea Announces HCV Treatment Study Results

Atea Pharmaceuticals to Release FY2025 Q1 Earnings on May 12 After-Market EST, Forecast EPS USD -0.4107

Co-Diagnostics

NewGenIvf

Liminatus Pharma

Agape ATP

Tradr 2X Long QBTS Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long RGTI Daily ETF

PicoCELA

Netcapital

Wheeler Real Estate

AVIR

Atea Pharmaceuticals held its Q1 2026 earnings call, reporting a strong financial position with $256 million in cash, ensuring a runway through 2027. The company is advancing its global Phase 3 HCV program, nearing completion of enrollment, with top-line data expected mid-year and year-end. Atea is also launching a new HEV program targeting immunocompromised patients, with a first-in-human study planned for mid-year. Management emphasized strategic positioning for a commercial launch in the HCV market, leveraging favorable dynamics.

Fidelity

Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript

Earnings Watch

Atea Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

Atea Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0

Atea Completes Share Buyback Program, Holding 0.97% of Own Shares

Tip Ranks

Atea Completes Share Buyback Program, Holding 0.97% of Own Shares

SMDV

In April 2026, small-cap stocks have demonstrated resilience amid geopolitical tensions and energy price fluctuations, with indices like the S&P MidCap 400 and Russell 2000 showing gains. Investors are encouraged to explore undervalued small-cap companies with solid fundamentals and insider activity. Notable mentions include Atea, Bilia, and Boozt, each showcasing growth potential and insider confidence through recent share purchases. Atea plans to distribute dividends, Bilia's net income rose, and Boozt completed a share repurchase program, indicating positive outlooks for these companies.

Simplywall

Direxion Small Cap Bull 3X

Pro Rsl 2000 Dvd Grw

SPDR Portfolio S&P 400 Mid Cap ETF

VG S&P M-Cap 400 Val

Avantis U.S. Small Cap Value

Pacer S&P MidCp 400 Qul FCF Arstcrts ETF

iShares Russell 2000

Global X Russell 2000 ETF

Vanguard Russell 2000

Vanguard Russell 2000 Value

SPDR S&P 600 S-Cp Val

VG S-Cp Grw

ISHRS Russ 2000 Growth

Xtrackers S&P MidCap 400 ESG ETF

ISHRS Russ 2000 Val

Vanguard Russell 2000 Growth

Undervalued Small Caps With Insider Activity In Global For April 2026

Atea Pharmaceuticals (NASDAQ:AVIR) shares rose 5.9% to $5.38 during trading, despite a 52% decline in volume compared to the average. Analysts have mixed ratings on the stock, with one Strong Buy, one Hold, and one Sell. The company reported a quarterly loss of ($0.57) EPS, missing estimates. Institutional investors hold 86.67% of the stock. Atea focuses on developing antiviral therapeutics, including treatments for COVID-19 and hepatitis C.

Market Beat

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 5.9%  - Here's Why

Atea Increases Treasury Share Holdings Under Ongoing Buyback Program

Atea Increases Treasury Share Holdings Under Ongoing Buyback Program

Atea Pharmaceuticals(AVIR.US)

Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript

Atea Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

Atea Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0

Atea Completes Share Buyback Program, Holding 0.97% of Own Shares

Undervalued Small Caps With Insider Activity In Global For April 2026

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 5.9% - Here's Why

Atea Increases Treasury Share Holdings Under Ongoing Buyback Program